Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group Phase II Trial of First-Line Irinotecan in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Cervix

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata^1,2

1966 • 2,159 citations

The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1961 • 685 citations

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

1997 • 434 citations

Phase I and pharmacokinetic trial of weekly CPT-11.

1993 • 300 citations

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.

1995 • 296 citations

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1991 • 275 citations

Effects of CPT‐11 in combination with other anti‐cancer agents in culture

1992 • 226 citations

Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.

1996 • 220 citations

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

1988 • 213 citations

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

1994 • 195 citations

Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance

1991 • 168 citations

Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.

1994 • 151 citations

Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

1997 • 135 citations

Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line

1992 • 100 citations

Cisplatin in advanced cancer of the cervix: an update.

1991 • 83 citations

Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study.

1987 • 79 citations

Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design.

1998 • 64 citations

Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix.

1998 • 63 citations

CPT-11: an original spectrum of clinical activity.

1996 • 63 citations

An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix

1997 • 58 citations

A Phase II Trial of CPT-11 in Recurrent Squamous Carcinoma of the Cervix: A Gynecologic Oncology Group Study

1998 • 52 citations

The role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in chemotherapy for lung cancer.

1994 • 45 citations

Chemotherapy as a palliative treatment in carcinoma of the uterine cervix.

1995 • 37 citations

A phase II study of irinotecan (CPT‐11) in patients with advanced squamous cell carcinoma of the cervix

1998 • 36 citations

A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix

1998 • 26 citations

A Phase II Study of 5-Fluorouracil/Cisplatinum in Recurrent Cervical Cancer

1990 • 22 citations

[Evaluation of a new anti-cancer drug regimen against uterine cervical cancer in nude mice].

1997 • 3 citations

Cited By (0)

Loading...